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INTRODUCTION:
A limitation of the use of the currently available anti-atrial fibrillation (AF) agents is the risk of induction of ventricular arrhythmias. This has prompted the development of atrial-specific antiarrhythmic agents. We have recently shown that ranolazine, an antianginal agent possessing antiarrhythmic properties , selectively affects sodium-channel dependent parameters in canine atria vs. ventricles and effectively suppresses AF in vitro (Burashnikov, et al., 2007) . Similar atrial selectivity of ranolazine as well as its anti-AF efficacy have been demonstrated in the porcine heart in vivo (Kumar, et al., 2009; Carvas, et al., 2010) .
Consistent with these experimental observations, clinical studies have shown anti-AF efficacy of ranolazine (Scirica, et al., 2007; Murdock, et al., 2008; Murdock, et al., 2009; Murdock, et al., 2010) . Propafenone, a potent sodium channel blocker, is used for termination as well as prevention of AF in the clinic (Fuster, et al., 2011; Alboni, et al., 2004) . The aim of the present study was to compare the electrophysiological effects of ranolazine and propafenone in isolated 
METHODS:
This investigation conforms to the Guide for Care and Use of Laboratory Animals published by the National Institutes of Health (NIH publication No 85-23, Revised 1996) and was approved by the ACUC of the Masonic Medical Research Laboratory. Experiments were performed using isolated arterially-perfused canine right atrial (RA) preparations and left ventricular (LV) arterially-perfused wedge preparations (≈ 2x1x1 cm). Detailed methods for isolation and perfusion of these preparations have been described in previous publications . Briefly, the preparations were dissected from hearts removed from anesthetized (sodium pentobarbital) adult mongrel dogs (20-25 kg) .
Unfolded RA with a rim of the right ventricle was cannulated and perfused through the ostium of the right coronary artery and the LV wedge was perfused through a branch of the left coronary artery. Unperfused tissue was removed with a razor blade or scissors. The cut ventricular and atrial branches were ligated using silk thread. After these procedures (performed in cold cardioplegic solution, 4-8 0 C), the preparations were transferred to a temperature-controlled bath and arterially perfused with Tyrode's solution by use of a roller pump. The composition of the Tyrode's solution was (in mM): NaCl 129, KCl 4, NaH 2 PO 4 0.9, NaHCO 3 20, CaCl 2 1.8, MgSO 4 0.5, and D-glucose 5.5, buffered with 95% O 2 and 5% CO 2 (37±0.5 0 C, pH=7.35)
Transmembrane action potential (AP) recordings (sampling rate 41 kHz) were obtained using standard or floating glass microelectrodes (2.7 M KCl, 10-25 MΩ DC resistance). A pseudo-electrocardiogram (ECG) was recorded using two electrodes consisting of Ag/AgCl half cells placed in the Tyrode's solution bathing the preparation, 1.0 to 1.2 cm from opposite ends of the atrial or ventricular coronary-perfused preparations ( Fig. 1 and 2 ). Conduction time was approximated by measuring the duration of the "P wave" complex in atria and the "QRS"
This article has not been copyedited and formatted. The final version may differ from this version. Maximum rate of rise of the AP upstroke (V max ): Stable AP recordings and V max measurements are difficult to obtain in vigorously contracting perfused preparations. In coronary-perfused atria and ventricles, the effects of propafenone and ranolazine on V max were determined by comparing the largest V max recorded at any given condition. Due to a substantial inter-preparation variability, V max values were normalized for each experiment and then averaged.
Experimental Protocols. The equilibration period for the preparations was 30-60 min. The concentrations of ranolazine (1.0, 5.0, 10.0 µM) and propafenone (0.3 and 1.5 µM) were increased in a step-wise manner, with at least 20 min for ranolazine and 40 min for propafenone at each concentration prior to start collecting the data. This difference reflects the various exposure durations that are required to achieve a steady-state in electrophysiological actions of the agents Delgado, et al., 1985) . The concentrations of the drugs used are within the therapeutic relevant ranges of ranolazine and propafenone achieved when the drugs are prescribed at their recommended doses Grant, 1996) . To compare the antiarrhythmic potential of propafenone and ranolazine, we used an acetylcholine (Burashnikov and Antzelevitch, 2003; Burashnikov, et al., 2007) . We determined the effect of propafenone and ranolazine to prevent (series 1) the induction of AF as well as, in different preparations, the effect of these drugs to terminate (series 2) persistent AF. In the first series, ACh was added to the perfusate ≥ 40 min after the start of 1.5 µM propafenone and ≥ 20 min after start of 10 µM ranolazine, followed by attempts to induce arrhythmias using programmed electrical stimulation (PES). In the second series, the effect of propafenone or ranolazine to terminate persistent AF was tested by adding these drugs to the coronary perfusate solution following 5-8 min of persistent AF. After AF termination, re-induction of the arrhythmia was attempted using PES.
Drugs: Ranolazine (Gilead Sciences, Palo Alto, CA), propafenone, and acetylcholine (both SIGMA, MO) were all dissolved in distilled water and each was prepared fresh as a stock of 1-10 mM before each experiment.
Statistics:
Statistical analysis was performed using paired or unpaired t tests and one way repeated measures or multiple comparison analysis of variance (ANOVA) followed by Bonferroni's test, as appropriate. All data are expressed as mean ± SD.
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 1) . Propafenone rate-dependently lengthened ERP much more than APD 75-90 in both atria and ventricles, thereby inducing a significant PRR in both chambers (Fig. 2) . Ranolazine induced rate-dependent atrial-selective prolongation of ERP and the development of PRR only in atria ( Fig. 2) .
DTE was significantly increased by propafenone in both atria and ventricles at 500 and 300 CLs (Fig. 3 ). In contrast, ranolazine increased DTE selectively in atria, with a much greater increase at 300 vs. 500 ms CL (Fig. 3 ). Propafenone potently depressed V max and increased conduction time similarly in atria and ventricles at a CL of 500 ms, but altered these parameters to a greater extent in atria vs. ventricles at a CL of 300 ms ( Fig. 4 and 5). Ranolazine produced atrial-selective reduction in V max and increase in conduction time, which was more pronounced at faster pacing rates ( Fig. 4 and 5). Ranolazine produced a weaker depression of V max and conduction velocity, compared to propafenone. Figure 4A reveals the mechanisms contributing to the atrial-selectivity of propafenone and ranolazine to reduce V max at rapid pacing rates.
Because of the slow repolarization phase of the atrial action potential and the effect of both propafenone and ranolazine to further slow phase 3, acceleration of rate leads to elimination of the diastolic interval in atria but not in the ventricles. Because much of the recovery from sodium channel block occurs during the diastolic interval, greater accumulation of block occurs in atria vs. ventricles at rapid rates of activation.
Propafenone vs. ranolazine: Anti-AF action
This article has not been copyedited and formatted. The final version may differ from this version. for each, PM, CL = 500 ms), permitting the induction of persistent AF in 100% of atria (10/10 atria). Addition of ACh (0.5 µM) to atrial preparations pretreated with propafenone (1.5 µM) and ranolazine (10 µM) abbreviated APD and ERP to an extent that was less than that observed in the absence of propafenone and ranolazine (Table) . Under these conditions, both agents were very effective in preventing the induction of persistent ACh-mediated AF, with propafenone being slightly more effective compared to ranolazine (Table) . In a different set of atrial preparations, we tested the effect of the two drugs to terminate persistent ACh-mediated AF. The addition of propafenone (1.5 µM) or ranolazine (10.0 µM) to the perfusion solution on the 5-8 th min of persistent AF terminated the arrhythmia in 8/10 and 8/12 atria, respectively (Fig. 6 , Table) . Average time for AF termination was 7±5 min for propafenone and 14±7 min for ranolazine. Both propafenone and ranolazine effectively prevented the re-induction of persistent AF (Table) . Brief episodes of non-sustained AF or atrial flutter (< 1 min duration) could still be induced in 3/8 and 5/8 atria in the presence of propafenone and ranolazine, respectively. These anti-AF actions of propafenone and ranolazine were associated with rate-dependent depression of excitability, making it impossible for the atria to beat at rapid rates such as those during AF (Fig. 6 ).
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DISCUSSION
The main result of the current experimental study is that while both ranolazine and propafenone effectively terminate ACh-mediated AF and prevent the induction of the arrhythmia, ranolazine, in contrast to propafenone, does it without producing significant electrophysiological effects in the ventricles.
Atrial selective sodium channel block and AF suppression
The risk of induction of ventricular proarrhythmia and/or organ toxicity is a major limitation of currently clinically available anti-AF agents (Fuster, et al., 2011) . The availability of atrial-specific or atrial-selective agents could obviate this problem. Block of I Kur has long been considered to be a promising atrial-selective approach for the management of AF. However, recent studies indicate that "pure" I Kur block is unlikely to be effective in suppressing AF (Burashnikov and Antzelevitch, 2008c; Burashnikov and Antzelevitch, 2008b; Ravens and Wettwer, 2011; Pandit, et al., 2011) .
We recently provided evidence in support of the hypothesis that atrial selective sodium channel block may effectively suppress AF without inducing ventricular arrhythmias (Burashnikov, et al., 2007) . This concept stemmed from the finding that certain biophysical properties (e.g., steady-state inactivation) of the sodium channels and of action potential morphology in atria differ from those in the ventricles (Burashnikov, et al., 2007) . Both ranolazine and amiodarone were shown to "take advantage" of these distinctions, producing significant depression of sodium channel-dependent parameters in canine atrial, but not in ventricular preparations, thus leading to effective suppression of AF at concentrations causing minimal to no effect on ventricular electrophysiology (Burashnikov, et al., 2007; Burashnikov, et al., 2008; Sicouri, et al., 2009; . The atrial selectivity of ranolazine as (Burashnikov, et al., 2007; Kumar, et al., 2009; Szel, et al., 2011; Carvas, et al., 2010) Atrialselective depression of sodium channel-mediated parameters in the canine heart has also been reported with exposure to chronic amiodarone and acute AZD1305 (Burashnikov, et al., 2008; . In a large clinical study in patients with non-ST segment elevation acute coronary syndrome (MERLIN-TIMI 36), treatment with ranolazine was associated with reduced incidence of supraventricular arrhythmias and a 30% reduction in new onset AF (Scirica, et al., 2007) . A number of relatively small clinical studies have shown a potent anti-AF efficacy of ranolazine for termination of paroxysmal AF (Murdock, et al., 2008; Murdock, et al., 2009; Murdock, et al., 2010) . In an exploratory (not placebo-randomized control) clinical study, ranolazine was found to be more effective than amiodarone in preventing post-operative AF (AF incidence was 17.5 vs. 26.5%, respectively) (Miles, et al., 2011) .
Ranolazine can inhibit early I Na , late I Na , I Kr , and late I Ca Burashnikov, et al., 2007) . Inhibition of early I Na by ranolazine is atrial-selective and markedly rate-dependent, which is consistent with the differential effect (atria vs. ventricle) of ranolazine on V max ( Figure   4 ), P-wave and QRS duration ( Figure 5 ) (Zygmunt, et al., 2011) . At therapeutically relevant concentrations (1-10 µM) ranolazine possesses anti-arrhythmic properties in the ventricles, primarily due to its potent effect to inhibit late I Na Wu, et al., 2004; , whereas in the atria, principally due to its effect to inhibit early I Na (Burashnikov, et al., 2007) . Unlike block of peak I Na , inhibition of late I Na does not directly affect peak I Na -mediated parameters such as V max , PRR, and DTE.
Propafenone is a well-studied and clinically used Class IC antiarrhythmic agent, which suppresses AF and prevents its recurrence, due largely to its ability to potently block early I Na This article has not been copyedited and formatted. The final version may differ from this version. (Fuster, et al., 2011) . Within a therapeutic range of concentrations, in addition to I Na , propafenone also produces relatively mild inhibition of I Kr , I to , I Ca , and β -adrenoreceptors (Grant, 1996) . We demonstrate an effect of propafenone to potently depress I Na -mediated parameters in both atrial and ventricular preparations at moderate to slow pacing rates. This is in sharp contrast to the effects of ranolazine to produce a potent depression of I Na -mediated parameters only in atria. However, the anti-AF efficacy of ranolazine was only slightly less than that of propafenone (Table) .
The electrophysiological effects of both propafenone and ranolazine at clinically-relevant concentrations, pacing rates, and temperature are due largely to inhibition of peak I Na and I Kr .
The functional potency of these drugs to inhibit peak I Na and I Kr depends critically on the heart chamber studied as well as pacing rate. Physiologically relevant IC 50 values for comparison of ranolaizne and propafenone are not available at present. Previous studies have reported IC 50 values for ranolazine inhibition of peak I Na of 285±170 and 286±150 µM for atrial and ventricular cells, respectively; however, the data were obtained at a slow pacing rate, 15 0 C, and -140 mV holding potential (Zygmunt, et al., 2011) . Judging from the effects of the drugs on peak I Na -mediated parameters (V max , PRR, DTE, etc), the potency of propafenone to block peak I Na in the ventricles is much greater than that of ranolazine. Differences in the relative potency of the two agents to suppress peak I Na in the atria is less obvious, particularly at a CL of 300 ms. The potency of propafenone and ranolazine to inhibit I Kr appears roughly comparable in that both agents produce a similar prolongation of APD 90 in atria and no change in the ventricles.
The ranolazine data reported in the current study are very similar to those previously published by our group (Burashnikov, et al., 2007) (both studies were conducted in canine coronary-perfused right atrial preparations and utilized similar experimental protocols).
This article has not been copyedited and formatted. The final version may differ from this version. Propafenone reduces V max and induces PRR similarly in atrial and ventricular guinea pig superfused preparations (Delgado, et al., 1985) . GE-68, an analog of propafenone, selectively prolongs atrial APD, but depresses V max to a similar extent in atrial and ventricular guinea pig superfused preparations (Lemmens-Gruber, et al., 1997) .
Propafenone is used for both conversion of paroxysmal AF and for long term maintenance of sinus rhythm in AF patient with relatively healthy hearts (Fuster, et al., 2011; Alboni, et al., 2004) . One of the clinical uses of propafenone is in the so-called "pill-in-the pocket" approach (Alboni, et al., 2004) . A disadvantage of propafenone is that its use is contraindicated in patients with structural heart disease (conditions encountered in many patients with AF) due to the risk of induction of life-threatening ventricular arrhythmias. Recent clinical studies suggest that a single dose of 2000 mg ranolazine may be effective as a "pill-in-thepocket" approach, converting 77% of AF patients, including patients with structural cardiac disease(s), with no significant adverse reactions (Murdock, et al., 2009; Murdock, et al., 2010) .
Considering the safety of ranolazine in patients with structural heart diseases (Koren, et al., 2007; Wilson, et al., 2009) , the "pill-in-the-pocket" approach utilizing ranolazine may prove to have a much wider applicability than previously used Class IC antiarrhythmic agents (i.e., propafenone and flecainide).
Atrial-selective APD prolongation potentiates atrial selectivity of I Na block
The primary anti-AF mechanism of propafenone and ranolazine in our study is related to the action of these drugs to block peak sodium channel current, I Na , especially at fast atrial rates.
This article has not been copyedited and formatted. The final version may differ from this version. The prolongation of APD 90 in atria by both agents likely contributes to the anti-AF effect of these agents both directly and indirectly (i.e., by enhancing the block of early I Na , Fig. 4 ). Atrialselective prolongation of APD 90 by ranolazine and propafenone is likely due to their effect to block I Kr Grant, 1996) . Indeed, specific I Kr block with E-4031 produces atrial-predominant prolongation of APD 90 and ERP in canine preparations at a CL of 500 ms (Burashnikov, et al., 2008) . A similar atrial-predominant effect of I Kr blockers to prolong ERP has been demonstrated in vivo in both canine and porcine hearts (Spinelli, et al., 1992; Wiesfeld, et al., 1996) . It is also noteworthy that neither propafenone (Gross and Castle, 1998 ) nor ranolazine (Zygmunt and Antzelevitch, unpublished) block I Kur and that I Kur inhibition abbreviates instead of prolonging APD 90 in "healthy" atria Wettwer, et al., 2004) .
Atrial selective prolongation of APD 90 induced by propafenone and ranolazine contributes to the abbreviation of the diastolic interval at rapid pacing rates in atria but not ventricles (Fig. 4) . Because much of the recovery of the sodium channels from block occurs during the diastolic interval (Whalley, et al., 1995) , the atrial selective prolongation of APD 90 enhances the effect of both drugs to depress I Na and I Na -mediated parameters in atria at rapid rates, thus potentiating their effects to suppress AF.
Atrial selectivity of I Na blockers: rapid vs. slow dissociation kinetics?
Both propafenone and ranolazine are predominantly open state sodium channel blockers (Whalley, et al., 1995; Wang, et al., 2008; Zygmunt, et al., 2011) . Amiodarone and AZD1305 are also atrial selective sodium channel blockers (Burashnikov, et al., 2008; . While amiodarone is primarily an inactivated-state sodium channel blockers (Whalley, et This article has not been copyedited and formatted. The final version may differ from this version. , 1995) , AZD1305 is a potent tonic blocker (i.e., inhibits sodium channel at the resting state) . Ranolazine produces little to no tonic block at normal resting membrane potential (Zygmunt, et al., 2011) . Thus, the available data suggest that preferential binding to a given state of the channel (i.e., open, inactivated, or resting) does not necessarily determine atrial selectivity of I Na blockers. The unbinding kinetics of propafenone and ranolazine appear to play a determining role. Propafenone dissociates slowly (τ ≥ 8 sec (Whalley, et al., 1995) ), whereas ranolazine dissociation is relatively rapid (τ = 1.6 sec (Burashnikov, et al., 2007) ). Consistent with this hypothesis, amiodarone, which has recently been shown to be an atrial-selective sodium channel blocker (Burashnikov, et al., 2008) , unbinds rapidly from the sodium channel (Whalley, et al., 1995) . Other factors that contribute to atrial selective inhibition of I Na include a more negative voltage-dependence of steady-state inactivation of the sodium channels, a more positive resting membrane potential, and a much slower phase 3 of the action potential in atria vs. ventricles (for detailed discussion see (Burashnikov and Antzelevitch, 2008a; Burashnikov and Antzelevitch, 2009; ).
Study Limitations.
Extrapolation of our results obtained from in vitro to in vivo animal models or to the clinic should be done with great caution. The absence of autonomic and hormonal influences, which can significantly modulate cardiac electrophysiology and thereby the pharmacological response to drugs, are among the limitations of in vitro preparations. In addition, our experiments were carried out using "healthy" atria and ventricles, whereas AF normally occurs in electrically and structurally remodeled atria. Atrial remodeling can significantly affect pharmacological responses.
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